E-LIB Suche - Ergebnisse für: Burris, Howard A.

1

A risk analysis of alpelisib-induced hyperglycemia in patie..:

Rodón, Jordi ; Demanse, David ; Rugo, Hope S....
Breast Cancer Research. 26 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

2

A phase I study of ATR inhibitor gartisertib (M4344) as a s..:

Burris, Howard A. ; Berlin, Jordan ; Arkenau, Tobias...
British Journal of Cancer. 130 (2024) 7 - p. 1131-1140 , 2024

Link: https://doi.org/10.1038/..

3

Plain Language Summary of the TOPAZ-1 Study: Durvalumab and..:

Oh, Do-Youn ; He, Aiwu Ruth ; Qin, Shukui...
Future Oncology. 19 (2023) 34 - p. 2277-2289 , 2023

Link: https://doi.org/10.2217/..

4

P526: SAFETY AND EFFICACY UPDATE FROM CLI120-001: A PHASE1B..:

Lech-Marańda, Ewa ; Szymańska, Agata ; Zaucha, Jan...
HemaSphere. 7 (2023) S3 - p. e27994b8 , 2023

Link: https://doi.org/10.1097/..

5

A real-world retrospective study of the use of Ki-67 testin..:

Brown, Jacqueline ; Scardo, Savannah ; Method, Michael...
BMC Cancer. 22 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

6

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Al..:

Lyou, Yung ; Rosenberg, Jonathan E. ; Hoffman-Censits, Jean...
Clinical Genitourinary Cancer. 20 (2022) 1 - p. 35-42 , 2022

Link: https://doi.org/10.1016/..

7

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist ..:

Yap, Timothy A. ; Gainor, Justin F. ; Callahan, Margaret K....
Clinical Cancer Research. 28 (2022) 17 - p. 3695-3708 , 2022

Link: https://doi.org/10.1158/..

8

A Phase II Study Evaluating Orteronel, an Inhibitor of Andr..:

Yardley, Denise A. ; Young, Robyn R. ; Adelson, Kerin B....
Clinical Breast Cancer. 22 (2022) 3 - p. 269-278 , 2022

Link: https://doi.org/10.1016/..

9

Efficacy and safety of rucaparib treatment in patients with..:

Kristeleit, Rebecca S. ; Drew, Yvette ; Oza, Amit M....
British Journal of Cancer. 128 (2022) 2 - p. 255-265 , 2022

Link: https://doi.org/10.1038/..

10

An open-label phase I dose-escalation study of the safety a..:

Liu, Joyce ; Burris, Howard ; Wang, Judy S....
Gynecologic Oncology. 163 (2021) 3 - p. 473-480 , 2021

Link: https://doi.org/10.1016/..

11

Safety and impact of dose reductions on efficacy in the ran..:

Burris, Howard A. ; Chan, Arlene ; Bardia, Aditya...
British Journal of Cancer. 125 (2021) 5 - p. 679-686 , 2021

Link: https://doi.org/10.1038/..

12

Characterization of patients with long-term responses to ru..:

Swisher, Elizabeth M. ; Kristeleit, Rebecca S. ; Oza, Amit M....
Gynecologic Oncology. 163 (2021) 3 - p. 490-497 , 2021

Link: https://doi.org/10.1016/..

13

First-in-human study of the safety, pharmacokinetics, and p..:

Falchook, Gerald ; Infante, Jeffrey ; Arkenau, Hendrik-Tobias...
EClinicalMedicine. 34 (2021) - p. 100797 , 2021

Link: https://doi.org/10.1016/..

14

First-In-Human, First-In-Class, Phase I Trial of the Fucosy..:

Do, Khanh T. ; Chow, Laura Quan Man ; Reckamp, Karen...
The Oncologist. 26 (2021) 11 - p. 925-e1918 , 2021

Link: https://doi.org/10.1002/..

15

A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib ..:

Weekes, Colin ; Lockhart, Albert ; LoRusso, Patricia...
The Oncologist. 25 (2020) 10 - p. 833-e1438 , 2020

Link: https://doi.org/10.1634/..